Esonix M 40 mg is a proton pump inhibitor (PPI) formulated to provide potent and long-lasting suppression of gastric acid secretion. It is used in the treatment and prevention of various acid-related gastrointestinal disorders. By irreversibly inhibiting the proton pump in gastric parietal cells, Esonix M 40 mg effectively controls both basal and stimulated acid secretion, offering sustained therapeutic benefit.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Proton Pump Inhibitor

Indications

Esonix M 40 mg is indicated for the treatment and management of:

• Gastroesophageal Reflux Disease (GERD)

• Healing of erosive esophagitis

• Maintenance of healing of erosive esophagitis

• Symptomatic GERD

• Reduction of NSAID-associated gastric ulcers

• Helicobacter pylori eradication (as part of triple therapy)

• Zollinger–Ellison syndrome

Pharmacology

Esonix M 40 mg suppresses gastric acid secretion by covalently binding to sulfhydryl groups of cysteine residues on the H⁺/K⁺-ATPase enzyme located on the secretory surface of gastric parietal cells. This action blocks the final step of acid production, leading to inhibition of both basal and stimulated acid secretion regardless of the stimulus.
Because this binding is irreversible, acid secretion resumes only after new enzyme synthesis, resulting in an antisecretory effect that lasts longer than 24 hours.

Dosage and Administration

Tablet or Capsule

Healing of Erosive Esophagitis

• 20 mg or 40 mg once daily for 4–8 weeks

• An additional 4–8 weeks may be considered if healing is incomplete

Maintenance of Healing of Erosive Esophagitis

• 20 mg once daily

• Controlled studies did not extend beyond 6 months

Symptomatic GERD

• 20 mg once daily for 4 weeks

• May be extended for an additional 4 weeks if symptoms persist

H. pylori Eradication (Triple Therapy)

• Esonix M 20 mg twice daily for 10 days

• Amoxicillin 1000 mg twice daily for 10 days

• Clarithromycin 500 mg twice daily for 10 days

Injection (IV Use)

• 20 mg or 40 mg once daily by slow intravenous injection (minimum 3 minutes)

• Or intravenous infusion over 10–30 minutes

Method of Administration

Intravenous Infusion Preparation

• Reconstitute one vial with 5 ml of 0.9% Sodium Chloride

• Further dilute to a final volume of 50 ml

• Final concentration: 0.8 mg/ml

Dose Administration

• 20 mg dose: Withdraw 25 ml and infuse over 10–30 minutes

• 10 mg dose: Withdraw 12.5 ml and infuse over 10–30 minutes

Drug Interactions

• Appears to be a selective inhibitor of the cytochrome P450 mono-oxygenase system

• No clinically significant drug interactions have been reported to date

• Reduction in gastric acid may affect vitamin B12 absorption and gastric bacterial colonization

• Possible effect on oral combined contraceptives cannot be ruled out

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Known hypersensitivity to Esonix M 40 mg or any component of the formulation

Side Effects

Reported side effects include:

• Headache

• Diarrhea

• Abdominal pain

Pregnancy and Lactation

• US FDA Pregnancy Category C

• Should be avoided during pregnancy and lactation unless the potential benefit outweighs the possible risk to the fetus or infant

Precautions and Warnings

• Exclude the possibility of gastric malignancy before initiating treatment for suspected gastric ulcer or dyspepsia

• When used in combination with antibiotics, refer to the prescribing information of the respective antibiotics

Storage Conditions

• Store in a dry place

• Protect from light and heat

• Keep out of reach of children

Reconstitution

• Reconstitute the dry powder with 5 ml of 0.9% Sodium Chloride for intravenous injection

• The reconstituted solution should be clear and colorless to slightly yellow.